WASHINGTON — The Centers for Medicare and Medicaid Services proposed a major payment bump for hospitals administering the cutting-edge gene therapies known as CAR-T treatments late Monday.

It’s a direct response to longstanding criticisms from the pharmaceutical industry, patient advocates, and hospitals that said Medicare’s subpar reimbursement rates for the new therapies — which can have list prices upward of $450,000 per patient — forced hospitals to choose between losing money or declining to offer the therapies at all.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I hope Gilead and Novartis would agree to set the price for Yescarta and Kymrish as close as possible to say within $500 of each other to get around this average nonsense!

Comments are closed.

Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy